Literature DB >> 1968964

Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.

H S Chan1, P S Thorner, G Haddad, V Ling.   

Abstract

Increased expression of P-glycoprotein is associated with multidrug resistance (MDR) in many cell lines. Significant levels of P-glycoprotein have been detected in a number of human tumors. The purpose of this study was to determine whether P-glycoprotein expression correlates with both response to chemotherapy and prognosis in soft tissue sarcoma of childhood. In a retrospective study, biopsy samples from 30 cases of rhabdomyosarcoma (RMS) and undifferentiated sarcoma (US) treated at The Hospital for Sick Children in Toronto were analyzed using a semiquantitative immunohistochemical procedure. P-glycoprotein was detected in nine patients, four at diagnosis, and five at subsequent biopsy. All nine patients relapsed after a clinical response (complete [CR] 55%, partial [PR] 45%) to chemotherapy. Twenty of 21 patients with consistently P-glycoprotein-negative tumors received chemotherapy and they all responded clinically (CR 80%, PR 20%). Only one of these 20 patients has relapsed. The probability of relapse-free survival was significantly different (P less than .000000012) in chemotherapy-treated patients whose tumors contained detectable levels of P-glycoprotein (n = 9), compared with those whose tumors contained no detectable P-glycoprotein (n = 20). The overall probability of survival was also significantly different in these two groups (P less than .0000267). Both relapse-free and overall survivals remained statistically different in the two groups of patients when analyzed by the log-rank method, after adjustment for differences in stages and sites. The incidence of other adverse prognostic factors in the two groups, for example, younger and older ages, low pretreatment lymphocyte counts, large tumors, and unfavorable histology were not significantly different. Thus, detectable P-glycoprotein appears to be an important adverse prognostic factor in children with soft tissue sarcoma, and consistent absence of the protein is associated with a favorable prognosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968964     DOI: 10.1200/JCO.1990.8.4.689

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  81 in total

1.  P-glycoprotein expression in soft-tissue sarcomas.

Authors:  H Nakanishi; A Myoui; T Ochi; K Aozasa
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Effect of mitogen-activated protein kinase signal transduction pathway on multidrug resistance induced by vincristine in gastric cancer cell line MGC803.

Authors:  Bo Chen; Feng Jin; Ping Lu; Xiang-Lan Lu; Ping-Ping Wang; Yun-Peng Liu; Fan Yao; Shu-Bao Wang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

3.  Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2).

Authors:  A R Alexanian; N S Arutyunian
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  Proceedings: Second International Symposium on Cytostatic Drug Resistance. Kiel, 1-2 November 1991. Abstracts.

Authors: 
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  p-Glycoprotein expression as a predictor of breast cancer recurrence.

Authors:  S Gregorcyk; Y Kang; D Brandt; P Kolm; G Singer; R R Perry
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

6.  P-Glycoprotein Expression in Indian Breast Cancer Patients with Reference to Molecular Subtypes and Response to Anthracycline-Based Chemotherapy-a Prospective Clinical Study from a Developing Country.

Authors:  Mudit Mehrotra; Akshay Anand; Kul Ranjan Singh; Surender Kumar; Nuzhat Husain; Abhinav Arun Sonkar
Journal:  Indian J Surg Oncol       Date:  2018-07-31

7.  Uptake of drugs and expression of P-glycoprotein in the rat 9L glioma.

Authors:  T Yamashima; T Ohnishi; Y Nakajima; T Terasaki; M Tanaka; J Yamashita; T Sasaki; A Tsuji
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

8.  Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.

Authors:  B Schott; D Londos-Gagliardi; C Ries; S Huet; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.

Authors:  R Perez-Soler; Y H Ling; Y Zou; W Priebe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.

Authors:  L Wang; C P Yang; S B Horwitz; P A Trail; A M Casazza
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.